

RESEARCH ARTICLE

Expression Pattern of *Axin2* During Chicken Development

Gesa Eckeï, Marion Böing, Beate Brand-Saberi, Gabriela Morosan-Puopolo*

Department of Anatomy and Molecular Embryology, Ruhr-University of Bochum, Bochum, Germany

* gabriela.morosan-puopolo@rub.de



Abstract

Canonical *Wnt*-signalling is well understood and has been extensively described in many developmental processes. The regulation of this signalling pathway is of outstanding relevance for proper development of the vertebrate and invertebrate embryo. *Axin2* provides a negative-feedback-loop in the canonical *Wnt*-pathway, being a target gene and a negative regulator. Here we provide a detailed analysis of the expression pattern in the development of the chicken embryo. By performing *in-situ* hybridization on chicken embryos from stage HH 04+ to HH 32 we detected a temporally and spatially restricted dynamic expression of *Axin2*. In particular, data about the expression of *Axin2* mRNA in early embryogenesis, somites, neural tube, limbs, kidney and eyes was obtained.

OPEN ACCESS

Citation: Eckeï G, Böing M, Brand-Saberi B, Morosan-Puopolo G (2016) Expression Pattern of *Axin2* During Chicken Development. PLoS ONE 11(9): e0163610. doi:10.1371/journal.pone.0163610

Editor: Thomas Brand, Imperial College London, UNITED KINGDOM

Received: June 11, 2016

Accepted: September 12, 2016

Published: September 28, 2016

Copyright: © 2016 Eckeï et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by DFG grant (Br 957/5-3) and the Myores project (511978) funded by the EC's Sixth Framework Program.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Axin2 (also called Axil or Conductin) is a homologue of Axin protein. It shares approximately 45% of amino acids with Axin [1, 2]. The Axin protein houses four highly conserved functional domains throughout the species [3–5]. The N-terminal RGS-domain has been found to interact with the tumour suppressor gene adenomatous polyposis coli (APC) [1, 6]. Central in the Axin protein, binding sites for β -catenin and for the glycogen-synthase kinase 3 beta (GSK-3 β) were described [4]. At the C-terminal region, the DIX-domain is located that resembles the sequence of a DIX—domain in dishevelled protein (Dvl) and promotes its interaction with Axin [7]. At its C-terminus, Axin also interacts with the protein phosphatase 2A (PP2A) [3, 8, 9]. Being responsible for the degradation of the downstream canonical *Wnt*-signalling pathway molecule β -catenin, Axin and *Axin2* function as negative regulators of the canonical *Wnt*-signalling pathway [5, 10–12]. The *Wnt*-signalling pathway is one of the best elucidated signalling pathways. First, the canonical *Wnt*-pathway was described, followed by at least two non-canonical pathways. The pathway of planar cell polarity (PCP) and the *Wnt*/ Ca^{2+} -pathway are referred to as non-canonical pathways [13–15]. These are described to establish orientation in epithelia (PCP) and to play a role in early embryonic ventral patterning (*Wnt*/ Ca^{2+} -pathway) ([16] for review). Canonical and non-canonical *Wnt*-signalling are known to be enmeshed with each other, as their members partially contribute to more than one pathway [17, 18] and several *Wnt* ligands were described to activate both canonical and non-canonical pathways [19–22]. However, in this study, only the canonical pathway is of relevance, constituting a venue for the

Axin family [10]. Central to canonical *Wnt*-signalling stands the transcriptional activator β -catenin. When entering the nucleus, β -catenin can displace transcriptional repressors such as Groucho [23] from the TCF/LEF transcription factor, which now activates the transcription of target genes ([24] for review). In the unstimulated cell, a multi-protein complex mediates the degradation of β -catenin via the ubiquitin proteasome pathway [25, 26]. For this purpose, β -catenin is phosphorylated by one of the two kinases of the complex, GSK-3 β or the casein kinase 1 (CK1). Axin acts as a central scaffold protein in the degradation complex by binding and thus bringing together all important components [3]. For this purpose, Axin and *Axin2* contain highly conserved regions. GSK-3 β phosphorylates β -catenin, which subsequently is ubiquitinated by the E3 ubiquitinase β TrCP and degraded by a proteasome [4, 27]. GSK-3 β further phosphorylates Axin itself, leading to stabilization of its interaction with β -catenin [4]. APC and one of the relevant receptors in *Wnt* pathway, the low density lipoprotein related receptor LRP 5/6 are also known to be substrates of GSK-3 β [28, 29]. Although GSK-3 β is capable of phosphorylating β -catenin alone, Axin unites both proteins, facilitating and significantly accelerating this process [30]. Finally, this process represses β -catenin in the cytoplasm to a level that prohibits its access to the nucleus. In the presence of APC, the turnover of β -catenin increases [6, 31]. Previous studies suggest a role for APC in the recruitment of several β -catenin molecules to the environment of the destruction complex [5, 32, 33]. Upon arrival of *Wnt*-ligands, they bind to the seven-pass transmembrane receptor Frizzled and to its co-receptor, the low density lipoprotein related protein receptor (LRP) 5 or 6 [34–36]. This heterodimeric complex binds Dvl at the cytoplasmic tail of Fz [37] and initiates the recruitment of Axin and kinases (Gsk3b or Ck1) to the membrane, mediating the dissociation of the β -catenin-destruction complex [29, 38, 39]. Several studies have been performed in order to elucidate the exact molecular scenario after *Wnt*-binding. For instance, *Wnt* was described to induce Dvl, that is thought to recruit Axin-bound GSK-3 β to the membrane, where the latter phosphorylates LRP 5/6 and as a consequence dissociates from Axin [29, 40]. The phosphorylation of LRP 5/6 can equally be achieved by CK1 [39, 41]. Axin priorly was dephosphorylated by another member of the β -catenin degradation complex, the protein phosphatase 1 (PP1) [42, 43]. Unphosphorylated Axin releases β -catenin [30, 40] and easily binds to LRP 5/6. Binding of Axin to Dvl that is connected to the cytoplasmic tail of Frizzled, is proposed to facilitate this initial recruitment [27]. Previous studies have further proposed a model for the formation of so called signalosomes, built from multiple associated LRP/Axin complexes [44]. As a result of the dissociation from the β -catenin-destruction complex, β -catenin is not degraded any more, cytoplasmic levels rapidly rise and it enters the nucleus [37]. A special function for *Axin2* was found, when discovering its transcriptional dependence on TCF/LEF motive [45]. *Axin2* expression therefore is initiated by canonical *Wnt*-signalling and provides a negative-feedback loop [27, 37, 45]. As this study aims to emphasize the relevance of *Axin2* in regulating the *Wnt*-signalling pathway, it is important to mention the state of the art regarding the role of canonical *Wnt*-pathway in development and in disease. During development, canonical *Wnt*-signalling is described to be required for proper posterior axis formation and for the formation of the head [46–48]. Moreover, *Wnt*-signalling is known to be indispensable in the developing central and peripheral nervous system [49]. It is described to be involved to the segmentation clock during somitogenesis [50] and in the development of several other structures and organs, such as the limbs, the kidney, the gastrointestinal system, the sensory organs and the lungs ([37, 49] for review). In the adult, deregulation of the *Wnt* pathway cause several cancers and *Wnt*-signalling is required for stem cell self renewal [51, 52]. The regulation of *Wnt*-signalling via Axin and *Axin2* impacts embryonic development and health in the adult, as described by many studies. Axin mutant mice failed to survive [11, 53] and display severe developmental defects. Mice with homozygous mutations in *Axin2* developed a secondary caudal body axis

[11] and exhibited malformations of the skull due to premature fusion of cranial structures [54]. This malformation is an equivalent to the human disease craniosynostosis, that is described to develop on the basis of *Axin2* mutations [55]. Another developmental defect associated with *Axin2* abnormalities in mice and human is familial tooth agenesis and oligodontia [56, 56, 57]. Further, Axin is related to hepatocellular cancer [58, 59], ovarian cancers [60] and to medulloblastomas [61]. *Axin2* mutations play a secondary role in familial adenomatous polyposis coli (FAP), when the causal mutation is not situated in APC and because proper function of APC requires Axin [62, 63]. Predisposition to colorectal cancer, when carrying mutations in *Axin2* is described [58, 63]. Shedding similar functions than Axin, *Axin2* was previously tested on its functional redundancy [54]. *Axin2* was shown to be able to at least partially compensate for mutated Axin when expressed in the respective cells. Axin however, is expressed in small amounts in all embryonic tissues, while *Axin2* expression was described to be restricted and dynamic during mouse development [11, 45]. Interestingly, Axin was described to be the limiting factor in *Wnt* regulation, referring to its low cytoplasmatic levels [64]. *Axin2* on the other hand, is highly expressed, suggesting an extensive role for *Axin2* regulation in certain tissues. This observation, together with the fact that *Axin2* is a target of *Wnt*-signalling, indicates the importance of *Axin2* mediated negative regulation in certain tissues. In this study, we demonstrate the dynamic expression pattern of *Axin2* in the development of the chick.

Materials and Methods

Embryos

Fertilized eggs of *Gallus gallus domesticus* were incubated at 37°C and 80% relative humidity. Eggs were provided by a local breeder (Sörries-Trockels Vermehrungszucht). Staging was performed according to Hamburger and Hamilton [65].

The obtained chicken embryos were isolated, fixed in 4% PFA for at least 24h. For description and analysis of the expression pattern of *Axin2* during chicken development, chicken embryos in developmental stages HH 04 to HH 32 were proceeded in *in-situ* hybridization.

Whole mount *in-situ* hybridization

Whole mount *in-situ* hybridization was performed as previously described [66], using *cAxin2* riboprobe for detection of *Axin2* transcripts in all embryonic tissue.

Generation of a riboprobe for *in-situ* hybridization. The probe for *cAxin2 in-situ* hybridization was generated from a pCMS-EGFP plasmid containing a full length *Axin2* coding sequence. It was restricted using EcoRV and SmaI to obtain a 835bp fragment binding from bp926 to bp1788 on *Axin2* mRNA (NCBI Reference Sequence: NC_006105.4). The purified fragment was blunted and cloned to pJET1.2/blunt Cloning Vector. From here, the fragment was excised using XbaI and XhoI and ligated to pBluescript II KS+ Vector. The obtained plasmid was suitable for generating a riboprobe in *in vitro* transcription.

Sectioning

Vibratome-sections. The embryos were embedded in 2, 5 – 4% agarose gel and sectioned with *Vibratome* (Leica VT 1000 S) to 50–80µm. Sections were collected and covered with cover slips and Aquatex (Merck).

Cryo-sections. *In-situ* hybridized chicken embryos were embedded in Leica tissue freezing medium[®] and frozen with liquid nitrogen. Obtained blocks were sectioned with Leica CM3050 S *cryo-stat*. Sections were collected on slides, dried and covered using Aquatex (Merck).

Ethic statement. According to German legislation, the use of embryonic vertebrates in an animal experiment needs approval only if the animal is in the last third of its embryonic development. In the case of chicken, this means that experiments done on animals before embryonic day 14 (E14) are not regarded as an animal experiment by the Tierschutzgesetz, and therefore, do not need approval or governmental permission.

The chicken embryos sacrificed for this work were between developmental stages HH+04 (E1) and HH32 (E7.5). All embryos were sacrificed at the end of the study by opening the shell and tearing the allantois and amnion with forceps. Thereafter, the embryos were immersed in 4% PFA/PBS solution for fixation. No permits were required for the described study, which complied with all relevant regulations.

Results and discussion

0.1 Expression pattern of *cAxin2* during early chicken embryogenesis

After whole mount *in-situ* hybridization, a dynamic expression pattern of *Axin2* was found from stages HH 04 to 32. In early embryogenesis, *Axin2* expression was observed in the primitive streak (ps) (Fig 1, A black arrow, B, C, D) and in the Hensen's node (hn) (Fig 1, B red arrow, C red arrow, D, E). Additionally, the head fold (hf) heavily expresses *Axin2* from stage HH 07 + onwards (Fig 1, B, C black arrows). During further development, in stage HH 10, *Axin2* transcripts were detectable in the Hensen's node (hn), posterior presomitic mesoderm (psm) (Fig 1, E) and medially in the freshly segmented paraxial mesoderm (dml-dorso-medial lip) (Fig 1, E.1 red arrow). Transversal sections were performed to analyse the expression of *Axin2* during early embryogenesis in detail. They present gastrulation and neurulation processes, where the maturation can be observed in a cranial to caudal axis. The green bars in the whole mount specimens indicate the sectioning level. Sections of HH stage 08 (Fig 1, C.1, C.2, C.3) show the caudally regressing primitive streak (ps) with the primitive groove (pg). The primitive folds (pf) of the ectoderm and the developing mesoderm underlying the primitive groove (pg) express *Axin2* (Fig 1, C.1, C.2, C.3). Further, the transversal section of the head fold (hf) in HH stage 08 (C.4) shows intense expression of *Axin2* in medial parts, facing towards the lumen of the anterior neuropore. In HH 09, during the primary neurulation process, cranially to Hensen's node (hn) (Fig 1, D, D.1, D.2), only little *Axin2* is expressed in the neural groove (ng) (Fig 1, D.1, D.2) and in the elongating notochord (nc) (Fig 1, D.1 and D.2). At this stage the head folds (hf) at mid-brain (mb) level have converged (Fig 1, D.3) and *Axin2* expression is increased in the medial neural folds. In Fig 1, E.2, E.3, E.4 and E.5 (HH 10), the segmental plate mesoderm (spm) is formed, as the neural folds (nf) extend distally to form the neural tube (nt). *Axin2* is expressed in the neural groove (ng) and in the notochord (nc) (Fig 1, E.4, E.5). At HH stage 10 more cranially, first somites (so) are shaped in the segmental plate mesoderm (Fig 1, E.2, E.3), as the neural folds (nf) fuse to form the neural tube (nt). In sections E.6 to E.8 (Fig 1), the development of the caudally shifted Hensen's node (hn) is depicted. *Axin2* expression is restricted to the central Hensen's node (Fig 1, E.6, E.7, E.8) expanding towards the ventral axial mesoderm (am). In picture E.6 (Fig 1), the prechordal mesoderm (pcm) is heavily stained for *Axin2*.

By stage HH 11, the expression of *Axin2* in the dorso-medial lip (dml) appears (Fig 2, A, A.1 black arrows). This expression intensifies as the somites mature (Fig 2, HH 14: B, black arrow and HH 15: C, C.1 black arrows). Additionally, the posterior neuropore (pnp) is intensively stained for *Axin2* (Fig 2, A, B, C). Regarding the head of the depicted embryos in Fig 2, *Axin2* expression is visible predominantly in the mid-brain (mb) (Fig 2, A, B.1, C white arrow). During secondary neurulation, which describes the elongation of the neural tube (nt) into the tail bud, *Axin2* is expressed centrally in the tail bud mesoderm (tbm) (Fig 2, C.2, C.3, C.4) in




Fig 1. Expression of *cAxin2* in stages HH 04+ to HH 10. Overviews and transversal sections of chicken embryos. Green bars in overviews (C, D, E) indicate sectioning level. (A) HH 04+: *Axin2* transcripts in *ps* (black arrow). (B) HH 07+: expression intensified in *ps*, *hn* (red arrow) and *hf* (black arrow). (C) HH 08: expression in *hf* (black arrow), *hn* (red arrow) and *ps*. (C.1) *Axin2* expression in *pf* and *pg*. (C.2) intense staining in the *pf*. (C.3) expression thickened ectoderm as a first step of neurulation. (C.4) transcripts in the most medial inner epithelium of the *hf*. (D) HH 09: expression in *hn*, faintly in the *psm* and in the *mb*. (D.1, D.2) expression in the *ng* and in the *nc*. (D.3) strong expression in the medial layer of the *hf*. (E) HH 10: strong *Axin2* expression in *hn* and *psm*, as in the *mb*. (E.1) higher magnification of the *so* and *nt* shows expression in the medial *so*, the *dml*. (E.2) faint staining in medio-dorsal epithelium of the early *so* and in the developing *nt*. (E.3) transcripts rarely detectable in the *nf* prior to closing. (E.4) expression of *Axin2* in the *nc* and in the annealing *nf*. (E.5) expression in the centre of the *nf* and in the *nc*. (E.6, E.7, E.8) upheaval of the *nf* in the distal-most *hn*. (E.6) expression in the centre of the future *nt* and in the *pcm*. (E.7, E.8) transcripts in the folding neuroectoderm expanding towards the *am*. *ps*-primitive streak, *hn*-Hensen's node, *hf*-head fold, *pf*-primitive folds, *pg*-primitive groove, *psm*-presomitic mesoderm, *mb*-mid-brain, *ng*-neural groove, *nc*-notochord, *so*-somites, *nt*-neural tube, *nf*-neural fold, *spm*-segmental plate mesoderm, *pcm*-prechordal mesoderm, *am*-axial mesoderm.

doi:10.1371/journal.pone.0163610.g001




Fig 2. Expression of *cAxin2* in stages HH 11 to HH 15. Overviews (A, B, C) and transversal sections of chicken embryos. Green bars in overviews indicate sectioning level (C). (A) HH 11: *Axin2* expression in the head, *pnp*, *nt* and (A, A.1) *dml* of the *so* (black arrow). (B) HH 14: strong expression in the *dml* (black arrow). (B.1) transversal section through the head at mid-brain level with transcripts in the medial head fold in the adjacent neighbouring mesenchyme (black arrow). (C) HH 15: *Axin2* expression in the brain (white arrow), the *dml* (C.1 black arrow) and in the *pnp*. (C.2) expression in the *snc* and in the ventral *snt*. (C.3, C.4) *Axin2* expression in the *tbm*. (C.5) section through head and neck with expression of *Axin2* in the *oc*, the neighbouring *hb* and the *ov*. *pnp*-posterior neuropore, *nt*-neural tube, *dml*-dorso-medial lip, *so*-somites, *snc*-secondary notochord, *snt*-secondary neural tube, *tbm*-tail bud mesoderm, *oc*-otic cup, *hb*-hind-brain, *ov*-optic vesicle.

doi:10.1371/journal.pone.0163610.g002

HH 15 and ventrally in the recently formed secondary neural tube (*snt*) and secondary notochord (*snc*) (Fig 2, C.2).

In stage HH 14 at mid-brain level (Fig 2, B.1), the anterior neuropore has closed and *Axin2* expression has shifted to a patch in the ventral mesoderm, flanking the mid-brain (*mb*) (Fig 2, B.1 black arrow). In HH stage 15, *Axin2* expression is detectable in the developing sensory organs, eye and ear, for the first time (Fig 2, C.5). *Axin2* mRNA was detected in the otic cup (*oc*) (Fig 2, C.5) and adjacent hind-brain (*hb*), as well as in the out-pocketing optic vesicle (*ov*) (Fig 2, C.5). The optic vesicle (*ov*) forms laterally from the prosencephalon, where *Axin2* is transcribed in the medial wall.

Previous studies have investigated the role of *Wnt*-signalling during gastrulation, neurulation, axis- and head formation. In the early patterning events of the vertebrate body, canonical *Wnt*-signalling is believed to first act as dorsalizing and later as posteriorizing signal [67, 68]. In concordance to that, several *Wnt*-mutant mice exhibit truncated posterior axis, lost tail formation and disturbed somitogenesis [69, 70]. Experiments in chicken and *Xenopus* resulted in axis duplication and disturbed head formation after *Wnt* overexpression [71]. Proper formation of the head requires *Wnt* inhibition in the anterior embryonic tissue [72–74]. Ectopic expression of *Wnt* inhibitors was found to induce notochord formation [75]. The examination of *Axin* knockouts revealed its function in ventralizing the respective tissue and in inhibiting posterior axis formation [11]. Furthermore, *Axin* loss of function in *Xenopus* resulted in disturbed closure of neural folds, head folds and the duplication of the allantois [76]. These findings together with the our new observed expression of *Axin2* during chicken embryogenesis support the idea that appropriate regulation *Wnt*-signalling via *Axin2* influences body patterning, axis elongation and head formation. The expression of several *Wnts* in the chicken primitive streak and Hensen's node reinforce this hypothesis [77].

0.2 Expression pattern of *cAxin2* in stages HH 17 to 32

At HH stage 17, the chicken limb buds (lb) are distinguishable, expressing *Axin2* mRNA from their onset (Fig 3, A red arrows). During the rapid outgrowth of the limb buds (lb) the *Axin2* expression increases (Fig 3, HH 19: C, HH 20: D.1, HH 21: E.3, HH 22: F.2). The apical ectodermal ridge (aer) is notably stained (Fig 3, D.1 white arrow, E.3 black arrowhead, F.2 black arrow). In somites (so), *Axin2* expression shifts from the medial somite to the intersomitic furrow (isf) (Fig 3, HH 21: E.1 white arrow; HH 22: F, F.2 white arrows). After whole mount *in-situ* hybridization, the neural tube (nt) is stained for *Axin2* in two longitudinal stripes, at first weakly (Fig 3, HH 19: C.1, HH 20: D.2 black arrowhead), then stronger (Fig 3, HH 21: E.1 black arrowhead, HH 22: F.1 black arrowhead). Moreover, the mesenchyme of the sprouting tail bud (tb) expresses *Axin2* (Fig 3, HH 17: A, HH 19: C.3 black arrowhead, HH 22: F.4 red arrow). As well as at other expression sites, *Axin2* transcription relatively increases during maturation of the respective tissue or organ. At the head region, *Axin2* is expressed in the otic vesicle (ov) (Fig 3, HH 17: A black arrow; HH 19: C.2 white arrow; HH 21: E.2 black arrowhead). Furthermore, the branchial arches (ba) are specifically stained after *Axin2 in-situ* hybridization (Fig 3, HH 19: C.2 black arrow, HH 21: E.2, HH 22: F.3). Moreover, the brain vesicles express *Axin2*.

HH 23 to 29 embryos (Fig 4) express *Axin2* in similar regions, compared to the earlier developmental stages, with little changes. *Axin2* is expressed in brain and otic vesicle (ov) throughout these stages (Fig 4, HH 24: B.1 white arrow). In addition, the branchial arches (ba) show intense staining (Fig 4, HH 24: B.1), which becomes restricted during development and predominantly was observed on the protuberances of the mandibular (Fig 4, HH 27: E black arrowhead, HH 28: F white arrow) and maxillary arch, respectively (Fig 4, HH 29: G white arrow). The expression pattern in the neural tube (nt) changes from two longitudinal lines (as described above) to one central line (Fig 4, HH 26: D.3; HH 27: E.1 white arrows). Another expression site of *Axin2* is presented in Fig 3, picture E. Here, the white arrow indicates an *Axin2* expression in the facial development. *Axin2* is still expressed in the limbs (lb) by stage HH 26 (Fig 4, D.1). Here, it is notable that in further developed stages the future shoulder is heavily stained (Fig 4, HH 26: D.1, HH 28: F and HH 29: G red arrows). The interdigital zones, where programmed cell death occurs, express *Axin2* (Fig 4, HH 28: F and HH 29: G black arrows). This observation was continuously found in the development of digits in later stages (Fig 4, HH 31: H black arrow and HH 32: I). Strong *Axin2* expression is also visible in these




Fig 3. Expression pattern of *cAxin2* from HH stage 17 to 22. (A) HH 17 embryo with *Axin2* expression in the brain, *lb* (red arrows), tail and *ov* (black arrow). (A.1) dorsal view: expression in the *dml* (white arrow). (B) HH 18: more prominent staining in the *lb* and in the *ba*. (C, C.1, C.2 & C.3) HH 19: *Axin2* transcripts in the *nt* (C.1) and *dml* (C.1, white arrow), in *lb* (C, C.1), in *ov* (C.2, white arrow), *ba* (C.2, black arrow) and in the tip of the tail (C.3, black arrow). (D, D.1, D.2) HH 20: similar expression of *cAxin2*. (D.1) the wing bud expresses *Axin2*, white arrow: *aer*. (D.2) dorsal view: prominent expression in *nt* (black arrowhead) and *isf* (white arrow). (E, E.1, E.2, E.3) HH 21: Transcripts in the tip of the tail (E, black arrowhead), in *nt* and *so* (E.1), in the otic anlage (E.2, black arrowhead) and in the developing *lb* (E.3). (F, F.1, F.2, F.3 and F.4) HH 22: consecutive expression of *Axin2* mRNA in *ba* (F, black arrow; F.3), *nt* (F.1, black arrow), *isf* (F, white arrow, F.2, white arrow) and tail (F.4, red arrow). *lb*-limb buds, *ov*-otic vesicle, *dml*-dorso medial lip, *ba*-branchial arches, *nt*-neural tube, *aer*-apical ectodermal ridge, *isf*-intersomitic furrow, *so*-somites.

doi:10.1371/journal.pone.0163610.g003

older stages' shoulders (Fig 4, HH 31: H and HH 32: I). The chicken external ear (*ee*) expresses *Axin2* as well (Fig 4, HH 31: H and HH 32: I red arrows). Finally, *Axin2* is expressed in the first rows of feather buds (*fb*) on the back of the farthest developed stages (Fig 4, HH 31: H, H.1 and HH 32: I.1 white arrows), as at the shoulders and hips. On the chicken eye, the developing scleral ossicles express *Axin2* (Fig 4, HH 32: I white arrow).

0.3 *Axin2* expression during somitogenesis

In transversal sections of *in-situ* hybridized chicken embryos, *Axin2* expression was found during somitic differentiation (Fig 5). Green bars in the whole mount specimens (A, B, C, D, E, F, G) indicate the levels, where the sections have been performed. In the segmented paraxial mesoderm, *Axin2* is expressed in the epithelial somites and in the differentiating dermomyotome. At HH stage 15 transcripts are mainly detectable in the medial and medio-dorsal wall of the




Fig 4. *Axin2* transcripts in chicken embryos from stage HH 23 to HH 32. (A) HH 23: expression pattern resembles what is described in Fig 2. Limbs, inner ear, brain, eye, and *tb* express *Axin2* (A). (B, B.1 & B.2) HH 24: *Axin2* expression in the *ov* (B.1, white arrow) and *ba* (B.1), as well as in *nt* and *isf* (B.2, dorsal view). (C, C.1) HH 25: *Axin2* is expressed at similar embryonic structures with little change. (D, D.1, D.2, D.3) HH 26: *Axin2* expression in *ba* (D, black and red arrow; D.2), *ov* (D.2), *lb* (D.1), brain (D), eye (D), *isf* (D.3, white arrow) and *nt* (D.3). (E) HH 27: *Axin2* transcripts in the facial whilst (E, white arrow), in the *ba* (black arrows), as well as in *lb*. The dorsal view (E.1) expression in the *nt* (white arrow). *Ba* display specific staining for *cAxin2* (HH 28: F & HH 29: G, white arrows). HH 28 and 29: intense expression in the embryonic shoulder (F & G, red arrows). Expression of *Axin2* in the forming interdigital spaces (F & G, black arrows). (H, H.1) HH 31: expression of *Axin2* mRNA in *lb* and apoptotic interdigital zones (H, black arrow), at the *ee* (H, red arrow) and in the *fb* (H & H.1, white arrows). (I, I.1) HH 32: *Axin2* transcripts in the eye (I, white arrow), *ee* (I, red arrow) and in the *fb* (I.1, white arrow). *lb*-limb buds, *ov*-otic vesicle, *ba*-branchial arches, *tb*-tail bud, *nt*-neural tube, *isf*-intersomitic furrow, *fb*-feather buds, *ee*-external ear.

doi:10.1371/journal.pone.0163610.g004

epithelial somites (Fig 5, A.1 black arrow). This expression gains intensity in stage HH 16 and 17 as the somite (*so*) matures (Fig 5, B.1, C.3). More cranially in HH 17, where somites have matured even further, deepithelialization of the somite (*so*) has begun (Fig 5, C.2). *Axin2* expression is relatively strong in the remaining medio-dorsal epithelium (Fig 5, C.2 black arrow) and in the mesenchyme ventrally flanking the neural tube (*nt*) (Fig 5, C.2 red arrow). Further cranially, where the dermomyotome is almost completely formed (Fig 5, C.1), *Axin2* expression was found in the most ventral parts of the forming *dml* of the dermomyotome (Fig 5,




Fig 5. *Axin2* expression during somitogenesis and in the developing neural tube. Transversal sections: green bars in overviews indicate sectioning level. (A) HH 15, overview; (A.1) expression in medial epithelial *so* (black arrow) and faintly all over the *nt*. (B) HH 16, overview; (B.1) increased expression in the medial somitic epithelium. (C) HH 17, overview; (C.1) *Axin2* in *dml* (black arrow), in the mesenchyme ventrally flanking the *nt* (red arrow) and predominantly in the dorsal *nt*. (C.2) Expression in dorso-medial somitic epithelium (black arrow), ventrally in the mesenchyme (red arrow) and all over the *nt*. (C.3) Expression in the medial epithelial *so*. (D) HH 19, overview; (D.1) expression in *dml* and *nt*; (D.2) expression restricted to dorsal *nt* (green arrow) and ventrally in the neighbouring tissue (red arrow). (E) HH 20, overview; (E.1) expression throughout the *dm*; (E.2) *Axin2* transcripts in the dorsal *nt* (green arrow), in the ventro-medially adjacent mesenchyme (red arrow) and weakly in the *dml*. (F) HH 22, overview; (F.1) *Axin2* in the dorsal-most *nt* (green arrow) and in the overlying ectoderm (black arrow). (G) HH27, overview; (G.1) *Axin2* expression in *rp*, *fp* (red arrow), *drg* (black arrow) and subectodermal space (green arrow). (H.1, H.2, H.3) *snt* of the tail. (H.1) HH 24, faint expression in all parts of the *snt*; (H.2) HH 27, restricted and intensified expression in the dorsal *snt* and in overlying subectodermal space; (H.3) HH 28, *Axin2* in dorsal most *snt* and subectodermal space. *so*-somite, *nt*-neural tube, *dml*-dorso medial lip, *dm*-dermomyotome, *rp*-roof plate, *fp*-floor plate, *drg*-dorsal root ganglion, *snt*-secondary neural tube.

doi:10.1371/journal.pone.0163610.g005

C.1 black arrow) and in a patch adjacent to the ventral neural tube (*nt*) (Fig 5, C.1 red arrow). In stage HH 19, when the dermomyotome is fully established, transcripts are visible in the ventrally facing margin of the *dml*, neighbouring the sclerotome (Fig 5, HH 19: D.1 black arrow). In HH stage 20, at limb level *Axin2* expression is detectable also in the ventro-lateral lip (*vll*) (Fig 5, E.1 wing level). In further development, this expression gets restricted to the dorsal half of the dermomyotome (*dm*), the epaxial myotome and appears more faintly (Fig 5, E.2 interlimb level).

In mice *Axin2* expression was found to oscillate in the segmental plate mesoderm and to occupy a central role for the segmentation of the presomitic mesoderm [50, 78]. We were able to detect *Axin2* expression in the posterior *psm* in chicken from stage HH 09 to HH 16 (Figs 1 and 3). In mice, the expression of *Wnt*-genes alternates with the expression of FGFs in the PSM [78], indicating a similar mechanism in chicken. Interestingly *Axin2* mutant mice still undergo segmentation with slight to average deviation [55, 78]. Additionally, *Axin2* transcripts were found during the maturation of the somites. In this process, a network of many different *Wnt*-molecules and other signals is described to play a role. The patterning of the somites is controlled by dorsalizing *Wnt1* and *Wnt3a* from the dorsal neural tube [79–81], such as *Wnt6* from the overlying ectoderm [82]. *Wnt11* was described to maintain the epithelial status of the *dml*, while *Wnt6* from the ectoderm maintains the epithelial ventro-lateral lip (VLL) [83]. Additionally, it was found that *Wnt1* and *Wnt3a* are required for the formation of the *dml* [81]. *Axin2* expression in the *dml* and its progenitors (Fig 5) indicate a potential role in the proper development of the *dml* and the deriving dermis. This hypothesis is supported when regarding the expression of *Axin2* in the dermal derived feather buds (Fig 4, H.1, I.1).

0.4 Expression pattern in the developing neural tube

Regarding the development of the neural tube, *Axin2* is expressed from neurulation to the differentiated mature neural tube (nt) (Figs 2 and 5). In Fig 5, the maturation of the neural tube (nt) is depicted. First, *Axin2* mRNA was detected in a sprinkled distribution all over the neural tube (nt) (Fig 5, HH 15: A.1, HH 16: B.1, HH 17: C.1 and HH 19: D.1), with an intensified region at the medio-dorsal neuroepithelium (Fig 5, HH 17: C.1, HH 19: D.1). More cranially in HH 19, this expression appears more intense at the dorsal third (Fig 5, D.2 green arrow), while faint sprinkled expression remains in the ventral half of the neural tube (nt) (Fig 5, D.2). By HH stage 20, predominantly the dorsal expression domain increases even more (Fig 5, E.2 green arrow). Further, the faint expression site in the neighbouring tissue at left and right ventral side of the neural tube (nt) expands dorsally (Fig 5, E.2 red arrow). When maturing, the neural tube (nt) expresses *Axin2* strongly in the dorso-medial neuroepithelium (Fig 5, HH 22: F.1 green arrow). Additionally, *Axin2* transcripts are found in the overlying ectoderm and the subectodermal mesenchyme flanking the dorsal neural tube (nt) (Fig 5, HH 22: F.1 black arrow). In HH 27, *Axin2* expression was observed in the dorsal most part of the neural tube (nt) and in the roof- and floor plate (rp)(fp) (Fig 5, G.1). The black arrow in G.1 (Fig 5) reveals to the tip of the dorsal root ganglion (drg) that heavily expresses *Axin2*. Further, the dorsal ectoderm and subectodermal space overlying the neural tube (nt) are intensively stained (Fig 5, G.1 green arrow).

Axin2 transcripts were also found in secondary neurulation in the tail bud (Fig 2, C.2, C.3, C.4). After secondary neurulation, the differentiating secondary neural tube (snt) heavily expresses *Axin2* (Fig 5, H.1, H.2, H.3). First, this expression is well distributed over the entire neuroepithelium (Fig 5, HH 24: H.1). During maturation, transcripts were observed in HH 27, (Fig 5, H.2) mainly in the dorsal half of the secondary neural tube (snt) as in the overlying subectodermal mesenchyme and ectoderm. By HH 28 the *Axin2* is missing in the ventral two thirds of the secondary neural tube (snt), but is expressed intensively in the dorsal third, such as in the ectoderm and subectodermal mesenchyme (Fig 5, H.3).

During the development and maturation of the neural tube, the establishment of a dorso-ventral axis through ventralizing *Shh* activity versus dorsalizing *Wnt*-signals has been described [84, 85]. The main *Wnt*-genes expressed in the dorsal neural tube and roof plate are *Wnt1* and *Wnt3a* [84, 86]. These promote neural proliferation [84, 87]. Therefore, after activation of dorsal *Wnt*-signalling in the chick, dorso-ventral patterning of the neural tube was

perturbed and mitogenic activity of neural progenitors was increased [88]. *Wnt1* and *Wnt3a* inhibition in mice, besides incomplete closure of the neural folds, displayed phenotypic alterations throughout the neural tube including partially absent basal-, roof- and floor plates [89]. In addition, *Wnts* have been identified to play a role in ventrally specified neural progenitors [86, 90]. The countless signalling molecules interacting with the *Wnt*-signalling pathway during neural tube maturation imply that *Axin2* expression and its negative-feedback-loop in canonical *Wnt*-signalling impact this neural development and the basic molecular functions will be of special interest in future research.

0.5 Expression pattern of *cAxin2* during limb development

Limb development in chicken starts from an out-bulged ridge of the somatic lateral plate mesoderm by stage HH 15. At HH stage 17 the wing bud heavily express *Axin2* predominantly in the dorsal mesenchyme (Fig 6, A.1 black arrow). The hind-limb bud at the same stage is slightly further developed and transcripts of *Axin2* are present in the thickened ectoderm, which gives rise to the apical ectodermal ridge (*aer*) (Fig 6, A.2), as well as at proximo-ventral margin of the lateral plate mesoderm (Fig 6, A.2 black arrow). In stages HH 18 to HH 20 *Axin2* is expressed in the dorsal mesenchyme of the rapidly outgrowing limb buds (Fig 6, B.1, C.1, D.1, D.2). Moreover, the apical ectodermal ridge (*aer*) is heavily stained for *Axin2* (Fig 6, B.1, C.1, D.1 black arrow, D.2). By stage HH 23, the transcripts in the dorsal mesenchyme are reduced, though the ectoderm and apical ectodermal ridge (*aer*) still express *Axin2* (Fig 6, E.1 black arrow). This expression was consistent in further developed stages (Fig 6, HH 25: F.1; HH 26: G.1; HH 27: H.1 black arrow; HH 28: I.1, I.2 and I.3). Moreover, when regarding the developing bones (*bo*) in HH stage 26 and 28, we verified *Axin2* mRNA at the marginal perichondrium (Fig 6, G.1 and I.3 black arrows).

Several members of the *Wnt* family are expressed in the developing limb ([37] for review). The outgrowth of the limb bud is mediated by the apical ectodermal ridge (*aer*) [91]. *Wnt* genes are described to initiate the formation of the limb bud (*Wnt2b*) from the lateral plate mesoderm as well as the *aer* (*Wnt3a*) [92]. The *aer* in chicken expresses *Wnt3a* that, by initiating fibroblast growth factor (FGF) expression, mediates the rapid cell proliferation in the mesenchymal progress zone (PZ) underlying the *aer* [93]. Non-canonical *Wnt7a* is expressed in the dorsal ectoderm of the chicken limb, being responsible for dorsalization [94, 95]. Its expression site overlaps an additional expression site for *Wnt3a* in the ectoderm during early limb growth [96]. As *Wnt7a* target genes are expressed in the mesenchyme underlying the dorsal ectoderm, it was suggested that their signalling ranges as far as the target gene expression [97]. We postulate a similar distance of signalling for the canonical *Wnt3a* from early dorsal limb ectoderm as a source for early *Axin2* expression in the dorsal limb mesenchyme. Mutations of *Wnt3a* and *Wnt7a* and FGFs in chicken embryo induced the expression of a gene responsible for a form of polydactyly in human, the Townes-Brock-Syndrome [98]. Later in the limb development, canonical *Wnt*-signalling is described to promote cell proliferation and the differentiation of connective tissue [99]. *Axin2* expression in accordance to our results was reported in the perichondrium of mice [99]. By describing the expression of *Axin2* in the chicken developing limb, we want to reveal its presumable function in regulating *Wnt*-signals that are involved in outgrowth, proliferation and differentiation.

0.6 Expression pattern of *Axin2* during chicken nephrogenesis

The kidney development in birds and mammals takes place in three generations of nephric precursors [100]. In this study, an *Axin2* expression in mesonephric development is described (Fig 7). In stage HH 19 the mesonephric duct (*md*) at leg level faintly expresses *Axin2* (Fig 7,




Fig 6. Expression of *Axin2* in chicken limb development. (A.1, wing bud, w) HH 17, strong expression of *Axin2* in the limb, predominantly in the dorsal most part (black arrow). (A.2) The leg bud (l) shows less staining, a patch in the ventro-proximal tissue expresses *Axin2* (black arrow). (B.1, leg bud) HH 18, transcripts in the dorsal mesenchyme and in the distal ectoderm. (C.1) HH 19, expression in the dorsal and most proximal mesenchyme of the wing bud. (HH 19, C.1; HH 20, D.1 black arrow; D.2) *Axin2* expression *aer*. (C.1) HH 19 and (D.1) HH 20, *Axin2* in dorsal subectodermal mesenchyme, in ectoderm and in the *aer*. (E.1, E.2) HH 23; (F.1) HH 25: Transcripts in the ectoderm and *aer* of the limb buds. (E.2–I.3) HH 23 to HH 28: the ectoderm expresses high levels of *Axin2*. (G.1) HH 26, black arrow; (I.3) HH 28, black arrow: the margins of the developing *bo* show transcripts of *Axin2*. *aer*-apical ectodermal ridge, *bo*-bones.

doi:10.1371/journal.pone.0163610.g006

A.1 black arrow). By HH 20 at interlimb level, the staining expands to the overlying coelomic epithelium (coe)(Fig 7, B.1 black arrow).

At leg level in HH 20, intense *Axin2* expression in the nephric duct (md-mesonephric duct) and coelomic epithelium (coe) is observed (Fig 7, B.2 black arrow). When further differentiating,




Fig 7. Expression of *Axin2* in nephric duct. *Axin2* mRNA expression in the *md* (HH 19: A.1, leg level, black arrow; HH 20: B.1, interlimb level, black arrow and B.2, leg level; HH23: C.1, caudal interlimb level, black arrow). The overlying thickened ectoderm strongly expresses *Axin2* from HH stage 20 (B.1 & B.2, black arrows). Pictures D.1 and E.1 demonstrate detectable transcripts in the cloacal ectoderm (HH 26: D.1, HH 28: E.1 black arrows). *md*-mesonephric duct.

doi:10.1371/journal.pone.0163610.g007

transcription of *Axin2* decreases, but is still detectable in mesonephric duct (*md*) and overlying coelomic epithelium (*coe*) (Fig 7, HH 23: C.1 black arrow). In addition, Fig 7 shows transversal sections of the cloaca, where *Axin2* is expressed predominantly in the coelomic epithelium (Fig 7, D.1, E.1. black arrows).

The role of *Wnt* in the developing kidney has been extensively studied in the past. *Wnt4* and *Wnt9b* were described to be expressed in the nephric duct and coelomic epithelium [101–103]. The initiation of tubulogenesis of the developing kidney requires canonical *Wnt4* and *Wnt9b* signals from the nephric duct [101, 102]. Later in development both *Wnt*-ligands were

described to act through the PCP and the Ca²⁺-dependent pathway as well [104–107]. As the *Wnt*-ligands partially activate different intracellular responses in the course of kidney development, the research faces a challenging aim in understanding this network. In *Xenopus* a model mediating the switch from canonical to non-canonical *Wnt*-signalling during nephrogenesis was proposed [108, 109]. However, canonical *Wnt*-signalling is known to mediate not only nephron induction, but also its orientation, cell proliferation, specification and differentiation [107, 110–113]. Alterations in canonical and non-canonical *Wnt*-signalling are known to cause polycystic kidney diseases [114, 115]. Taken together, we suggest that *Axin2* might impact kidney development by regulating *Wnt*-signalling as indicated, through its expression in the nephric duct and coelom epithelium. The *Axin2* expression in the coelomic epithelium could possibly hint a role for *Axin2* in the development of the derived Mullerian-duct that develops to form the female genitals. As male gonads develop from the nephric or Wolffian-duct, *Axin2* might be involved in this developmental process as well.

0.7 *cAxin2* expression in developing chicken eye

The chicken eye initially develops, as the prosencephalon out-pockets and the optic vesicle (ov) invaginates to the head mesenchyme. *Axin2* in this process is expressed in the proximal layer of the bi-layered optic vesicle (ov) (Fig 8, HH 15: A.1, black arrow). By stage HH 16 the lens vesicle (lv) has formed from the ectoderm (Fig 8, B.1). *Axin2* transcripts are still detectable mainly in the proximal layer of the optic cup (oc) (Fig 8, B.1, HH 17: C.1 black arrow). An additional expression in the subectodermal mesenchyme overlying the optic cup (oc) and surrounding the lens vesicle (lv) is established at stage HH 18 (Fig 8, D.1 black arrow). While the lens vesicle (lv) expresses little *Axin2* in the inner lens epithelium (Fig 8, HH 19: E.1 and HH 20: F.1, F.2, F.3 red arrows), transcripts in the optic cup (oc) are found in both proximal and distal layer at the epithelial margins facing towards the vesicular space (Fig 8: HH 19: E.1 black arrow, HH 20: F.4 black arrow). In the following observed stages, the proximal layer of the optic cup (oc) has formed the retinal pigmented epithelium (rpe), whereas the distal layer differentiates into the retina [116]. *Axin2* expression was found only in the lens (Fig 8, HH 24: H.3 red arrow), ectoderm and subectodermal mesenchyme covering the eye (Fig 8, HH 24: H.1 and H.2 black arrows). Regarding the formation of the optic nerve (on) and optic chiasm (och), *Axin2* expression is observable in the approaching and fusing neuroepithelial layers (Fig 8, HH 25: I.1, HH 26: J.1, HH 27: K.1 black arrows). Further, *Axin2* is expressed in the future cornea covering the eye (Fig 8, HH 25: I.1, HH 26: J.1, HH 27: K.2 black arrow, HH 28: L.1 and L.2 black arrows) and in the posterior lens epithelium (Fig 8, HH 26: J.2 and J.3; HH 27: K.1 and K.2 red and green arrows).

Anteriorly expressed inhibitors of canonical *Wnt* signals are required for the initiation of the eye as described in zebrafish [117, 118]. Later, *Wnt2b* is expressed in the proliferative lens epithelium [119], retinal pigmented epithelium (rpe) and periphery of the optic cup [120–122]. Further, *Wnt3* and *Wnt11* were found to be expressed in the outer layer of the chicken optic cup [122]. *Wnt2b* was described to be responsible for maintaining the proliferative state of neural progenitors in the retina in chick [123]. Previous studies have reported a depigmentation of the retinal pigmented epithelium (rpe) after disruption of *Wnt2b* signalling in the chicken eye [120]. Our observed *Axin2* expression in the lens overlaps with regions of increased cell proliferation, which express *Wnt*-ligands as well [122, 124, 125]. The chicken developing cornea and corneal stroma cells express *Wnt3a* and *Wnt9b* [126]. Interestingly, a subgroup of the disease familial adenomatous polyposis coli (FAP), which is caused by a truncation in APC or *Axin2*, the Gardner syndrome, includes a congenital hypertrophy of the rpe [127]. Additionally, some cases of tetra amelia, which is the result of homozygous *Wnt3* mutations, exhibit optic malformations [128].




Fig 8. *Axin2* transcripts in optic development. Transversal sections through the developing eye in *in-situ* hybridized embryos. (A.1) HH 15: the primary *ov* expresses *Axin2* in the proximal layer (black arrow). (B.1) HH 16: *Axin2* expression in both layers of the bi-layered secondary *oc*. (C.1) HH 17: *Axin2* expression in the proximal epithelium of the *oc* (black arrow). (D.1) HH 18: *Axin2* expression in the proximal layer of the *oc* (red arrow). The ectoderm surrounding the invaginating, *lv* (black arrow) expresses *Axin2*. (D.2) HH 18: A section through the rostral most part of the *oc*, with highest expression rate in these margins. (E.1) HH 19: the proximal layer of the *lv* expresses *Axin2* (red arrow) as well as the *oc* in both layers adjacent to the vesicular space (black arrow). (F.1, F.2, F.3, F.4) HH 20: expression in the ectoderm surrounding the eye, in the directly underlying mesenchyme, in the epithelium of the *oc* towards the lumen (F.1, black arrow) and in the lens epithelium (F.1, F.2, F.3, red arrows). (HH 23: G.1; HH 24: H.1 and H.2, black arrows; HH 25: I.1; HH 26: J.1, J.2, J.3; HH 27: K.2, black arrow, HH 28: L.1, L.2, black arrows) *Axin2* expression in the ectoderm and subectodermal mesenchyme (future cornea). (HH 25: I.1, black arrow; HH 26: J.1, black arrow, HH 27: K.1, black arrow) *cAxin2* expression in the developing *on* and *och*. (H.3, HH 24; K.2, HH 27) expression of *Axin2* in the developing lens (red and green arrows). *ov*-optic vesicle, *oc*-optic cup, *lv*-lens vesicle, *on*-optic nerve, *och*-optic chiasm, *rpe*-retinal pigmented epithelium.

doi:10.1371/journal.pone.0163610.g008

Conclusion

In the present study, we describe the expression pattern of avian *Axin2* during embryonic development. We found a dynamic, temporally and spatially restricted expression pattern in many developing structures and tissues. In the early development of the chick, *Axin2* was

expressed in the primitive streak and underlying mesoderm, in the neural folds and in the head fold. It was additionally expressed during secondary neurulation in the tailbud mesenchyme. Here, the pre-somitic mesoderm as well transcribes *Axin2*. We were able to detect such expression in the posterior *psm* and during the maturation of the somites in its medial epithelium and in the *dml*. By this developmental stage, transcripts were also detectable in the brain and differentiating neural tube. In the developing limb a dynamic expression was found. Furthermore, we detected *Axin2* mRNA in the nephric duct and coelomic epithelium. Regarding the head of the chicken embryo, *Axin2* was expressed in branchial arches and sensory anlagen. Later in development, expression in feather buds, interdigital spaces, external ear and scleral ossicles on the eye was observed.

The expression of *Axin2* in mice was previously found in the primitive streak, head folds, neural tube, branchial arches I and II (maxillary and mandibular arch), *psm* and *dml*, tailbud, limbs, kidney and brain [45, 78].

These findings are mainly consistent to the expression we found in the chick. Additionally, we were able to show *Axin2* expression in the developing eye and in the otic vesicle. With this study we want to point out the often neglected impact of *Axin2* in many *Wnt*-dependant developmental processes. While *Wnt*-ligands are extensively studied, investigating their regulation through *Axin2* in the respective tissues might help understanding the interactions of different signalling factors.

Acknowledgments

We want to thank Houmani R. and Wulf S. for excellent technical assistance and Herrmann B. for *conductin* probe.

Author Contributions

Conceptualization: GE MB BBS GMP.

Data curation: GE.

Formal analysis: GE GMP.

Funding acquisition: BBS.

Investigation: GE MB BBS GMP.

Methodology: GE MB BBS GMP.

Project administration: BBS.

Resources: BBS.

Supervision: BBS GMP.

Visualization: GE.

Writing – original draft: GE.

Writing – review & editing: GE GMP.

References

1. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with β -catenin, APC, and GSK3 β . *Science*. 1998; 280(5363):596–599. doi: [10.1126/science.280.5363.596](https://doi.org/10.1126/science.280.5363.596) PMID: [9554852](https://pubmed.ncbi.nlm.nih.gov/9554852/)

2. Yamamoto H, Kishida S, Uochi T, Ikeda S, Koyama S, Asashima M, et al. Axin, a Member of the Axin Family, Interacts with Both Glycogen Synthase Kinase 3 β and β -Catenin and Inhibits Axis Formation of *Xenopus* Embryos. *Molecular and cellular biology*. 1998; 18(5):2867–2875. doi: [10.1128/MCB.18.5.2867](https://doi.org/10.1128/MCB.18.5.2867) PMID: [9566905](https://pubmed.ncbi.nlm.nih.gov/9566905/)
3. Kikuchi A. Roles of Axin in the Wnt signalling pathway. *Cellular signalling*. 1999; 11(11):777–788. doi: [10.1016/S0898-6568\(99\)00054-6](https://doi.org/10.1016/S0898-6568(99)00054-6) PMID: [10617280](https://pubmed.ncbi.nlm.nih.gov/10617280/)
4. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3 β and β -catenin and promotes GSK-3 β -dependent phosphorylation of β -catenin. *The EMBO journal*. 1998; 17(5):1371–1384. doi: [10.1093/emboj/17.5.1371](https://doi.org/10.1093/emboj/17.5.1371) PMID: [9482734](https://pubmed.ncbi.nlm.nih.gov/9482734/)
5. Nakamura T, Hamada F, Ishidate T, Anai Ki, Kawahara K, Toyoshima K, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with β -catenin, GSK-3 β and APC and reduces the β -catenin level. *Genes to Cells*. 1998; 3(6):395–403. doi: [10.1046/j.1365-2443.1998.00198.x](https://doi.org/10.1046/j.1365-2443.1998.00198.x) PMID: [9734785](https://pubmed.ncbi.nlm.nih.gov/9734785/)
6. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of β -catenin by human Axin and its association with the APC tumor suppressor, β -catenin and GSK3 β . *Current Biology*. 1998; 8(10):573–581. doi: [10.1016/S0960-9822\(98\)70226-X](https://doi.org/10.1016/S0960-9822(98)70226-X) PMID: [9601641](https://pubmed.ncbi.nlm.nih.gov/9601641/)
7. Kishida S, Yamamoto H, Hino Si, Ikeda S, Kishida M, Kikuchi A. DIX domains of Dvl and Axin are necessary for protein interactions and their ability to regulate β -catenin stability. *Molecular and cellular biology*. 1999; 19(6):4414–4422. doi: [10.1128/MCB.19.6.4414](https://doi.org/10.1128/MCB.19.6.4414) PMID: [10330181](https://pubmed.ncbi.nlm.nih.gov/10330181/)
8. Luo W, Lin SC. Axin: a master scaffold for multiple signaling pathways. *Neurosignals*. 2004; 13(3):99–113. doi: [10.1159/000076563](https://doi.org/10.1159/000076563) PMID: [15067197](https://pubmed.ncbi.nlm.nih.gov/15067197/)
9. Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. *Journal of Biological Chemistry*. 1999; 274(6):3439–3445. doi: [10.1074/jbc.274.6.3439](https://doi.org/10.1074/jbc.274.6.3439) PMID: [9920888](https://pubmed.ncbi.nlm.nih.gov/9920888/)
10. Kishida M, Koyama S, Kishida S, Matsubara K, Nakashima S, Higano K, et al. Axin prevents Wnt-3a-induced accumulation of β -catenin. *Oncogene*. 1999; 18(4). doi: [10.1038/sj.onc.1202388](https://doi.org/10.1038/sj.onc.1202388) PMID: [10023673](https://pubmed.ncbi.nlm.nih.gov/10023673/)
11. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL, et al. The mouse Fusedlocus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. *Cell*. 1997; 90(1):181–192. doi: [10.1016/S0092-8674\(00\)80324-4](https://doi.org/10.1016/S0092-8674(00)80324-4) PMID: [9230313](https://pubmed.ncbi.nlm.nih.gov/9230313/)
12. Sakanaka C, Weiss JB, Williams LT. Bridging of β -catenin and glycogen synthase kinase-3 β by axin and inhibition of β -catenin-mediated transcription. *Proceedings of the National Academy of Sciences*. 1998; 95(6):3020–3023. doi: [10.1073/pnas.95.6.3020](https://doi.org/10.1073/pnas.95.6.3020) PMID: [9501208](https://pubmed.ncbi.nlm.nih.gov/9501208/)
13. Kohn AD, Moon RT. Wnt and calcium signaling: β -catenin-independent pathways. *Cell calcium*. 2005; 38(3):439–446. doi: [10.1016/j.ceca.2005.06.022](https://doi.org/10.1016/j.ceca.2005.06.022) PMID: [16099039](https://pubmed.ncbi.nlm.nih.gov/16099039/)
14. Katoh M. WNT/PCP signaling pathway and human cancer (review). *Oncology reports*. 2005; 14(6):1583–1588. PMID: [16273260](https://pubmed.ncbi.nlm.nih.gov/16273260/)
15. Barrow JR. Wnt/PCP signaling: a veritable polar star in establishing patterns of polarity in embryonic tissues. In: *Seminars in cell & developmental biology*. vol. 17. Elsevier; 2006. p. 185–193. doi: [10.1016/j.semcdb.2006.04.002](https://doi.org/10.1016/j.semcdb.2006.04.002) PMID: [16765615](https://pubmed.ncbi.nlm.nih.gov/16765615/)
16. Komiya Y, Habas R. Wnt signal transduction pathways. *Organogenesis*. 2008; 4(2):68–75. doi: [10.4161/org.4.2.5851](https://doi.org/10.4161/org.4.2.5851) PMID: [19279717](https://pubmed.ncbi.nlm.nih.gov/19279717/)
17. Semenov MV, Habas R, MacDonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. *Cell*. 2007; 131(7):1378. doi: [10.1016/j.cell.2007.12.011](https://doi.org/10.1016/j.cell.2007.12.011) PMID: [18160045](https://pubmed.ncbi.nlm.nih.gov/18160045/)
18. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. *Genes & development*. 2010; 24(22):2517–2530. doi: [10.1101/gad.1957710](https://doi.org/10.1101/gad.1957710) PMID: [21078818](https://pubmed.ncbi.nlm.nih.gov/21078818/)
19. van Amerongen R, Fuerer C, Mizutani M, Nusse R. Wnt5a can both activate and repress Wnt/ β -catenin signaling during mouse embryonic development. *Developmental biology*. 2012; 369(1):101–114. doi: [10.1016/j.ydbio.2012.06.020](https://doi.org/10.1016/j.ydbio.2012.06.020) PMID: [22771246](https://pubmed.ncbi.nlm.nih.gov/22771246/)
20. Cha SW, Tadjuidje E, Tao Q, Wylie C, Heasman J. Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in *Xenopus* axis formation. *Development*. 2008; 135(22):3719–3729. doi: [10.1242/dev.029025](https://doi.org/10.1242/dev.029025) PMID: [18927149](https://pubmed.ncbi.nlm.nih.gov/18927149/)
21. Kestler HA, Kühl M. From individual Wnt pathways towards a Wnt signalling network. *Philosophical Transactions of the Royal Society of London B: Biological Sciences*. 2008; 363(1495):1333–1347. doi: [10.1098/rstb.2007.2251](https://doi.org/10.1098/rstb.2007.2251) PMID: [18192173](https://pubmed.ncbi.nlm.nih.gov/18192173/)
22. Tao Q, Yokota C, Puck H, Kofron M, Birsoy B, Yan D, et al. Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in *Xenopus* embryos. *Cell*. 2005; 120(6):857–871. doi: [10.1016/j.cell.2005.01.013](https://doi.org/10.1016/j.cell.2005.01.013) PMID: [15797385](https://pubmed.ncbi.nlm.nih.gov/15797385/)

23. Daniels DL, Weis WI. β -catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. *Nature structural & molecular biology*. 2005; 12(4):364–371. doi: [10.1038/nsmb912](https://doi.org/10.1038/nsmb912) PMID: [15768032](https://pubmed.ncbi.nlm.nih.gov/15768032/)
24. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? *Genes & development*. 2006; 20(11):1394–1404. doi: [10.1101/gad.1424006](https://doi.org/10.1101/gad.1424006) PMID: [16751178](https://pubmed.ncbi.nlm.nih.gov/16751178/)
25. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β -catenin. *The EMBO journal*. 1999; 18(9):2401–2410. doi: [10.1093/emboj/18.9.2401](https://doi.org/10.1093/emboj/18.9.2401) PMID: [10228155](https://pubmed.ncbi.nlm.nih.gov/10228155/)
26. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β -catenin is a target for the ubiquitin–proteasome pathway. *The EMBO journal*. 1997; 16(13):3797–3804. doi: [10.1093/emboj/16.13.3797](https://doi.org/10.1093/emboj/16.13.3797) PMID: [9233789](https://pubmed.ncbi.nlm.nih.gov/9233789/)
27. Huang H, He X. Wnt/ β -catenin signaling: new (and old) players and new insights. *Current opinion in cell biology*. 2008; 20(2):119–125. doi: [10.1016/j.ceb.2008.01.009](https://doi.org/10.1016/j.ceb.2008.01.009) PMID: [18339531](https://pubmed.ncbi.nlm.nih.gov/18339531/)
28. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3 β to the APC- β -catenin complex and regulation of complex assembly. *Science*. 1996; 272(5264):1023–1026. doi: [10.1126/science.272.5264.1023](https://doi.org/10.1126/science.272.5264.1023) PMID: [8638126](https://pubmed.ncbi.nlm.nih.gov/8638126/)
29. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. *Nature*. 2005; 438(7069):873–877. doi: [10.1038/nature04185](https://doi.org/10.1038/nature04185) PMID: [16341017](https://pubmed.ncbi.nlm.nih.gov/16341017/)
30. Jho Eh, Lomvardas S, Costantini F. A GSK3 β phosphorylation site in axin modulates interaction with β -catenin and Tcf-mediated gene expression. *Biochemical and biophysical research communications*. 1999; 266(1):28–35. doi: [10.1006/bbrc.1999.1760](https://doi.org/10.1006/bbrc.1999.1760) PMID: [10581160](https://pubmed.ncbi.nlm.nih.gov/10581160/)
31. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β -catenin. *Journal of Biological Chemistry*. 1998; 273(18):10823–10826. doi: [10.1074/jbc.273.18.10823](https://doi.org/10.1074/jbc.273.18.10823) PMID: [9556553](https://pubmed.ncbi.nlm.nih.gov/9556553/)
32. Fagotto F, Jho Eh, Zeng L, Kurth T, Joos T, Kaufmann C, et al. Domains of axin involved in protein–protein interactions, Wnt pathway inhibition, and intracellular localization. *The Journal of cell biology*. 1999; 145(4):741–756. doi: [10.1083/jcb.145.4.741](https://doi.org/10.1083/jcb.145.4.741) PMID: [10330403](https://pubmed.ncbi.nlm.nih.gov/10330403/)
33. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, Kikuchi A. Complex formation of adenomatous polyposis coli gene product and Axin facilitates glycogen synthase kinase-3 β -dependent phosphorylation of β -catenin and down-regulates β -catenin. *Journal of Biological Chemistry*. 2000; 275(44):34399–34406. doi: [10.1074/jbc.M003997200](https://doi.org/10.1074/jbc.M003997200) PMID: [10906131](https://pubmed.ncbi.nlm.nih.gov/10906131/)
34. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol*. 2004; 20:781–810. doi: [10.1146/annurev.cellbio.20.010403.113126](https://doi.org/10.1146/annurev.cellbio.20.010403.113126) PMID: [15473860](https://pubmed.ncbi.nlm.nih.gov/15473860/)
35. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, et al. LDL-receptor-related proteins in Wnt signal transduction. *Nature*. 2000; 407(6803):530–535. doi: [10.1038/35035117](https://doi.org/10.1038/35035117) PMID: [11029007](https://pubmed.ncbi.nlm.nih.gov/11029007/)
36. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/ β -catenin signaling: arrows point the way. *Development*. 2004; 131(8):1663–1677. doi: [10.1242/dev.01117](https://doi.org/10.1242/dev.01117) PMID: [15084453](https://pubmed.ncbi.nlm.nih.gov/15084453/)
37. Clevers H. Wnt/ β -catenin signaling in development and disease. *Cell*. 2006; 127(3):469–480. doi: [10.1016/j.cell.2006.10.018](https://doi.org/10.1016/j.cell.2006.10.018) PMID: [17081971](https://pubmed.ncbi.nlm.nih.gov/17081971/)
38. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, et al. A mechanism for Wnt coreceptor activation. *Molecular cell*. 2004; 13(1):149–156. doi: [10.1016/S1097-2765\(03\)00484-2](https://doi.org/10.1016/S1097-2765(03)00484-2) PMID: [14731402](https://pubmed.ncbi.nlm.nih.gov/14731402/)
39. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stanek P, et al. Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transduction. *Nature*. 2005; 438(7069):867–872. doi: [10.1038/nature04170](https://doi.org/10.1038/nature04170) PMID: [16341016](https://pubmed.ncbi.nlm.nih.gov/16341016/)
40. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3 β associations that regulate β -catenin stabilization are mediated by $G\alpha$ proteins. *Current Biology*. 2005; 15(22):1989–1997. doi: [10.1016/j.cub.2005.10.050](https://doi.org/10.1016/j.cub.2005.10.050) PMID: [16303557](https://pubmed.ncbi.nlm.nih.gov/16303557/)
41. Schwarz-Romond T, Metcalfe C, Bienz M. Dynamic recruitment of axin by Dishevelled protein assemblies. *Journal of cell science*. 2007; 120(14):2402–2412. doi: [10.1242/jcs.002956](https://doi.org/10.1242/jcs.002956) PMID: [17606995](https://pubmed.ncbi.nlm.nih.gov/17606995/)
42. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases β -catenin from the axin complex. *Genes & development*. 1999; 13(14):1768–1773. doi: [10.1101/gad.13.14.1768](https://doi.org/10.1101/gad.13.14.1768) PMID: [10421629](https://pubmed.ncbi.nlm.nih.gov/10421629/)
43. MacDonald BT, Tamai K, He X. Wnt/ β -catenin signaling: components, mechanisms, and diseases. *Developmental cell*. 2009; 17(1):9–26. doi: [10.1016/j.devcel.2009.06.016](https://doi.org/10.1016/j.devcel.2009.06.016) PMID: [19619488](https://pubmed.ncbi.nlm.nih.gov/19619488/)

44. Bilić J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. *Science*. 2007; 316(5831):1619–1622. doi: [10.1126/science.1137065](https://doi.org/10.1126/science.1137065) PMID: [17569865](https://pubmed.ncbi.nlm.nih.gov/17569865/)
45. Jho Eh, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/ β -catenin/Tcf signaling induces the transcription of *Axin2*, a negative regulator of the signaling pathway. *Molecular and cellular biology*. 2002; 22(4):1172–1183. doi: [10.1128/MCB.22.4.1172-1183.2002](https://doi.org/10.1128/MCB.22.4.1172-1183.2002) PMID: [11809808](https://pubmed.ncbi.nlm.nih.gov/11809808/)
46. Popperl H, Schmidt C, Wilson V, Hume C, Dodd J, Krumlauf R, et al. Misexpression of *Cwnt8C* in the mouse induces an ectopic embryonic axis and causes a truncation of the anterior neuroectoderm. *Development*. 1997; 124(15):2997–3005. PMID: [9247341](https://pubmed.ncbi.nlm.nih.gov/9247341/)
47. McMahon AP, Moon RT. Ectopic expression of the proto-oncogene *int-1* in *Xenopus* embryos leads to duplication of the embryonic axis. *Cell*. 1989; 58(6):1075–1084. doi: [10.1016/0092-8674\(89\)90506-0](https://doi.org/10.1016/0092-8674(89)90506-0) PMID: [2673541](https://pubmed.ncbi.nlm.nih.gov/2673541/)
48. Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C, Birchmeier W. Requirement for β -catenin in anterior-posterior axis formation in mice. *The Journal of cell biology*. 2000; 148(3):567–578. doi: [10.1083/jcb.148.3.567](https://doi.org/10.1083/jcb.148.3.567) PMID: [10662781](https://pubmed.ncbi.nlm.nih.gov/10662781/)
49. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of β -catenin in mice. *Genes & development*. 2008; 22(17):2308–2341. doi: [10.1101/gad.1686208](https://doi.org/10.1101/gad.1686208) PMID: [18765787](https://pubmed.ncbi.nlm.nih.gov/18765787/)
50. Aulehla A, Wiegraeb W, Baubet V, Wahl MB, Deng C, Taketo M, et al. A β -catenin gradient links the clock and wavefront systems in mouse embryo segmentation. *Nature cell biology*. 2008; 10(2):186–193. doi: [10.1038/ncb1679](https://doi.org/10.1038/ncb1679) PMID: [18157121](https://pubmed.ncbi.nlm.nih.gov/18157121/)
51. Clevers H, Nusse R. Wnt/ β -catenin signaling and disease. *Cell*. 2012; 149(6):1192–1205. doi: [10.1016/j.cell.2012.05.012](https://doi.org/10.1016/j.cell.2012.05.012) PMID: [22682243](https://pubmed.ncbi.nlm.nih.gov/22682243/)
52. Polakis P. The many ways of Wnt in cancer. *Current opinion in genetics & development*. 2007; 17(1):45–51. doi: [10.1016/j.gde.2006.12.007](https://doi.org/10.1016/j.gde.2006.12.007) PMID: [17208432](https://pubmed.ncbi.nlm.nih.gov/17208432/)
53. Perry WL, Vasicek TJ, Lee JJ, Rossi JM, Zeng L, Zhang T, et al. Phenotypic and molecular analysis of a transgenic insertional allele of the mouse *Fused* locus. *Genetics*. 1995; 141(1):321–332. PMID: [8536979](https://pubmed.ncbi.nlm.nih.gov/8536979/)
54. Chia IV, Costantini F. Mouse axin and axin2/conductin proteins are functionally equivalent in vivo. *Molecular and cellular biology*. 2005; 25(11):4371–4376. doi: [10.1128/MCB.25.11.4371-4376.2005](https://doi.org/10.1128/MCB.25.11.4371-4376.2005) PMID: [15899843](https://pubmed.ncbi.nlm.nih.gov/15899843/)
55. Yu HMI, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, et al. The role of *Axin2* in calvarial morphogenesis and craniosynostosis. *Development*. 2005; 132(8):1995–2005. doi: [10.1242/dev.01786](https://doi.org/10.1242/dev.01786) PMID: [15790973](https://pubmed.ncbi.nlm.nih.gov/15790973/)
56. Lohi M, Tucker AS, Sharpe PT. Expression of *Axin2* indicates a role for canonical Wnt signaling in development of the crown and root during pre- and postnatal tooth development. *Developmental Dynamics*. 2010; 239(1):160–167. doi: [10.1002/dvdy.22047](https://doi.org/10.1002/dvdy.22047) PMID: [19653310](https://pubmed.ncbi.nlm.nih.gov/19653310/)
57. Lammi L, Arte S, Somer M, Järvinen H, Lahermo P, Thesleff I, et al. Mutations in *AXIN2* cause familial tooth agenesis and predispose to colorectal cancer. *The American Journal of Human Genetics*. 2004; 74(5):1043–1050. doi: [10.1086/386293](https://doi.org/10.1086/386293) PMID: [15042511](https://pubmed.ncbi.nlm.nih.gov/15042511/)
58. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Molecular and cellular biology*. 2002; 22(4):1184–1193. doi: [10.1128/MCB.22.4.1184-1193.2002](https://doi.org/10.1128/MCB.22.4.1184-1193.2002) PMID: [11809809](https://pubmed.ncbi.nlm.nih.gov/11809809/)
59. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. *AXIN1* mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of *AXIN1*. *Nature genetics*. 2000; 24(3):245–250. doi: [10.1038/73448](https://doi.org/10.1038/73448) PMID: [10700176](https://pubmed.ncbi.nlm.nih.gov/10700176/)
60. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of β -catenin deregulation in ovarian endometrioid adenocarcinomas. *Cancer research*. 2001; 61(22):8247–8255. PMID: [11719457](https://pubmed.ncbi.nlm.nih.gov/11719457/)
61. Dahmen R, Koch A, Denkhau D, Tonn J, Sörensen N, Berthold F, et al. Deletions of *AXIN1*, a component of the WNT/wingless pathway, in sporadic medulloblastomas. *Cancer research*. 2001; 61(19):7039–7043. PMID: [11585731](https://pubmed.ncbi.nlm.nih.gov/11585731/)
62. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*. 1997; 1332(3):F127–F147. doi: [10.1016/S0304-419X\(97\)00008-5](https://doi.org/10.1016/S0304-419X(97)00008-5)
63. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, et al. Elevated expression of *axin2* and *hnkd* mRNA provides evidence that Wnt/ β -catenin signaling is activated in human colon tumors. *Proceedings of the National Academy of Sciences*. 2001; 98(26):14973–14978. doi: [10.1073/pnas.261574498](https://doi.org/10.1073/pnas.261574498) PMID: [11752446](https://pubmed.ncbi.nlm.nih.gov/11752446/)

64. Lee E, Salic A, Krüger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. *PLoS Biol.* 2003; 1(1):e10. doi: [10.1371/journal.pbio.0000010](https://doi.org/10.1371/journal.pbio.0000010) PMID: [14551908](https://pubmed.ncbi.nlm.nih.gov/14551908/)
65. Hamburger V, Hamilton HL. A series of normal stages in the development of the chick embryo. *Journal of morphology.* 1951; 88(1):49–92. doi: [10.1002/jmor.1050880104](https://doi.org/10.1002/jmor.1050880104) PMID: [24539719](https://pubmed.ncbi.nlm.nih.gov/24539719/)
66. Nieto MA, Patel K, Wilkinson DG. In situ hybridization analysis of chick embryos in whole mount and tissue sections. *methods in cell biology.* 1996; 51:219. doi: [10.1016/S0091-679X\(08\)60630-5](https://doi.org/10.1016/S0091-679X(08)60630-5) PMID: [8722478](https://pubmed.ncbi.nlm.nih.gov/8722478/)
67. Hikasa H, Sokol SY. Wnt signaling in vertebrate axis specification. *Cold Spring Harbor perspectives in biology.* 2013; 5(1):a007955. doi: [10.1101/cshperspect.a007955](https://doi.org/10.1101/cshperspect.a007955) PMID: [22914799](https://pubmed.ncbi.nlm.nih.gov/22914799/)
68. Durston A. Time, space and the vertebrate body axis. In: *Seminars in cell & developmental biology.* vol. 42. Elsevier; 2015. p. 66–77. doi: [10.1016/j.semcdb.2015.05.005](https://doi.org/10.1016/j.semcdb.2015.05.005) PMID: [26003049](https://pubmed.ncbi.nlm.nih.gov/26003049/)
69. Takada S, Stark KL, Shea MJ, Vassileva G, McMahon JA, McMahon AP. Wnt-3a regulates somite and tailbud formation in the mouse embryo. *Genes & development.* 1994; 8(2):174–189. doi: [10.1101/gad.8.2.174](https://doi.org/10.1101/gad.8.2.174) PMID: [8299937](https://pubmed.ncbi.nlm.nih.gov/8299937/)
70. Cunningham TJ, Kumar S, Yamaguchi TP, Ducrest G. Wnt8a and Wnt3a cooperate in the axial stem cell niche to promote mammalian body axis extension. *Developmental Dynamics.* 2015; 244(6):797–807. doi: [10.1002/dvdy.24275](https://doi.org/10.1002/dvdy.24275) PMID: [25809880](https://pubmed.ncbi.nlm.nih.gov/25809880/)
71. Niehrs C. Regionally specific induction by the Spemann–Mangold organizer. *Nature Reviews Genetics.* 2004; 5(6):425–434. doi: [10.1038/nrg1347](https://doi.org/10.1038/nrg1347) PMID: [15153995](https://pubmed.ncbi.nlm.nih.gov/15153995/)
72. Thisse B, Wright CV, Thisse C. Activin-and Nodal-related factors control antero–posterior patterning of the zebrafish embryo. *Nature.* 2000; 403(6768):425–428. doi: [10.1038/35000200](https://doi.org/10.1038/35000200) PMID: [10667793](https://pubmed.ncbi.nlm.nih.gov/10667793/)
73. Xu PF, Houssin N, Ferri-Lagneau KF, Thisse B, Thisse C. Construction of a vertebrate embryo from two opposing morphogen gradients. *Science.* 2014; 344(6179):87–89. doi: [10.1126/science.1248252](https://doi.org/10.1126/science.1248252) PMID: [24700857](https://pubmed.ncbi.nlm.nih.gov/24700857/)
74. Glinka A, Wu W, Onichtchouk D, Blumenstock C, Niehrs C. Head induction by simultaneous repression of Bmp and Wnt signalling in *Xenopus*. *Nature.* 1997; 389(6650):517–519. doi: [10.1038/39092](https://doi.org/10.1038/39092) PMID: [9333244](https://pubmed.ncbi.nlm.nih.gov/9333244/)
75. Yasuo H, Lemaire P. Role of Goosecoid, Xnot and Wnt antagonists in the maintenance of the notochord genetic programme in *Xenopus* gastrulae. *Development.* 2001; 128(19):3783–3793. PMID: [11585804](https://pubmed.ncbi.nlm.nih.gov/11585804/)
76. Gluecksohn-Schoenheimer S. The effects of a lethal mutation responsible for duplications and twinning in mouse embryos. *Journal of Experimental Zoology.* 1949; 110(1):47–76. doi: [10.1002/jez.1401100105](https://doi.org/10.1002/jez.1401100105) PMID: [18113441](https://pubmed.ncbi.nlm.nih.gov/18113441/)
77. Chapman SC, Brown R, Lees L, Schoenwolf GC, Lumsden A. Expression analysis of chick Wnt and frizzled genes and selected inhibitors in early chick patterning. *Developmental dynamics.* 2004; 229(3):668–676. doi: [10.1002/dvdy.10491](https://doi.org/10.1002/dvdy.10491) PMID: [14991722](https://pubmed.ncbi.nlm.nih.gov/14991722/)
78. Aulehla A, Wehrle C, Brand-Saber B, Kemler R, Gossler A, Kanzler B, et al. Wnt3a plays a major role in the segmentation clock controlling somitogenesis. *Developmental cell.* 2003; 4(3):395–406. doi: [10.1016/S1534-5807\(03\)00055-8](https://doi.org/10.1016/S1534-5807(03)00055-8) PMID: [12636920](https://pubmed.ncbi.nlm.nih.gov/12636920/)
79. Marcelle C, Stark MR, Bronner-Fraser M. Coordinate actions of BMPs, Wnts, Shh and noggin mediate patterning of the dorsal somite. *Development.* 1997; 124(20):3955–3963. PMID: [9374393](https://pubmed.ncbi.nlm.nih.gov/9374393/)
80. Hirsinger E, Duprez D, Jouve C, Malapert P, Cooke J, Pourquié O. Noggin acts downstream of Wnt and Sonic Hedgehog to antagonize BMP4 in avian somite patterning. *Development.* 1997; 124(22):4605–4614. PMID: [9409677](https://pubmed.ncbi.nlm.nih.gov/9409677/)
81. Ikeya M, Takada S. Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. *Development.* 1998; 125(24):4969–4976. PMID: [9811581](https://pubmed.ncbi.nlm.nih.gov/9811581/)
82. Schubert FR, Mootosamy RC, Walters EH, Graham A, Tumiotto L, Münsterberg AE, et al. Wnt6 marks sites of epithelial transformations in the chick embryo. *Mechanisms of development.* 2002; 114(1):143–148. doi: [10.1016/S0925-4773\(02\)00039-4](https://doi.org/10.1016/S0925-4773(02)00039-4) PMID: [12175501](https://pubmed.ncbi.nlm.nih.gov/12175501/)
83. Geetha-Loganathan P, Nimmagadda S, Huang R, Christ B, Scaal M. Regulation of ectodermal Wnt6 expression by the neural tube is transduced by dermomyotomal Wnt11: a mechanism of dermomyotomal lip sustainment. *Development.* 2006; 133(15):2897–2904. doi: [10.1242/dev.02464](https://doi.org/10.1242/dev.02464) PMID: [16818447](https://pubmed.ncbi.nlm.nih.gov/16818447/)
84. Chesnutt C, Burrus LW, Brown AM, Niswander L. Coordinate regulation of neural tube patterning and proliferation by TGF β and WNT activity. *Developmental biology.* 2004; 274(2):334–347. doi: [10.1016/j.ydbio.2004.07.019](https://doi.org/10.1016/j.ydbio.2004.07.019) PMID: [15385163](https://pubmed.ncbi.nlm.nih.gov/15385163/)

85. Wilson L, Maden M. The mechanisms of dorsoventral patterning in the vertebrate neural tube. *Developmental biology*. 2005; 282(1):1–13. doi: [10.1016/j.ydbio.2005.02.027](https://doi.org/10.1016/j.ydbio.2005.02.027) PMID: [15936325](https://pubmed.ncbi.nlm.nih.gov/15936325/)
86. Hollyday M, McMahon JA, McMahon AP. Wnt expression patterns in chick embryo nervous system. *Mechanisms of development*. 1995; 52(1):9–25. doi: [10.1016/0925-4773\(95\)00385-E](https://doi.org/10.1016/0925-4773(95)00385-E) PMID: [7577679](https://pubmed.ncbi.nlm.nih.gov/7577679/)
87. Megason SG, McMahon AP. A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. *Development*. 2002; 129(9):2087–2098. PMID: [11959819](https://pubmed.ncbi.nlm.nih.gov/11959819/)
88. Alvarez-Medina R, Cayuso J, Okubo T, Takada S, Martí E. Wnt canonical pathway restricts graded Shh/Gli patterning activity through the regulation of Gli3 expression. *Development*. 2008; 135(2):237–247. doi: [10.1242/dev.012054](https://doi.org/10.1242/dev.012054) PMID: [18057099](https://pubmed.ncbi.nlm.nih.gov/18057099/)
89. Augustine KA, Liu ET, Sadler T. Interactions of Wnt-1 and Wnt-3a are essential for neural tube patterning. *Teratology*. 1995; 51(2):107–119. doi: [10.1002/tera.1420510209](https://doi.org/10.1002/tera.1420510209) PMID: [7660319](https://pubmed.ncbi.nlm.nih.gov/7660319/)
90. Yu W, McDonnell K, Taketo MM, Bai CB. Wnt signaling determines ventral spinal cord cell fates in a time-dependent manner. *Development*. 2008; 135(22):3687–3696. doi: [10.1242/dev.021899](https://doi.org/10.1242/dev.021899) PMID: [18927156](https://pubmed.ncbi.nlm.nih.gov/18927156/)
91. Saunders JW. The proximo-distal sequence of origin of the parts of the chick wing and the role of the ectoderm. *Journal of Experimental Zoology*. 1948; 108(3):363–403. doi: [10.1002/jez.1401080304](https://doi.org/10.1002/jez.1401080304) PMID: [18882505](https://pubmed.ncbi.nlm.nih.gov/18882505/)
92. Kawakami Y, Capdevila J, Büscher D, Itoh T, Esteban CR, Belmonte JCI. WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo. *Cell*. 2001; 104(6):891–900. doi: [10.1016/S0092-8674\(01\)00285-9](https://doi.org/10.1016/S0092-8674(01)00285-9) PMID: [11290326](https://pubmed.ncbi.nlm.nih.gov/11290326/)
93. Johnson RL, Tabin CJ. Molecular models for vertebrate limb development. *Cell*. 1997; 90(6):979–990. doi: [10.1016/S0092-8674\(00\)80364-5](https://doi.org/10.1016/S0092-8674(00)80364-5) PMID: [9323126](https://pubmed.ncbi.nlm.nih.gov/9323126/)
94. Parr BA, Shea MJ, Vassileva G, McMahon AP. Mouse Wnt genes exhibit discrete domains of expression in the early embryonic CNS and limb buds. *Development*. 1993; 119(1):247–261. PMID: [8275860](https://pubmed.ncbi.nlm.nih.gov/8275860/)
95. Dealy CN, Roth A, Ferrari D, Brown AM, Kosher RA. Wnt-5a and Wnt-7a are expressed in the developing chick limb bud in a manner suggesting roles in pattern formation along the proximodistal and dorsoventral axes. *Mechanisms of development*. 1993; 43(2):175–186. doi: [10.1016/0925-4773\(93\)90034-U](https://doi.org/10.1016/0925-4773(93)90034-U) PMID: [8297789](https://pubmed.ncbi.nlm.nih.gov/8297789/)
96. Kengaku M, Capdevila J, Rodriguez-Esteban C, De La Peña J, Johnson RL, Belmonte JCI, et al. Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud. *Science*. 1998; 280(5367):1274–1277. doi: [10.1126/science.280.5367.1274](https://doi.org/10.1126/science.280.5367.1274) PMID: [9596583](https://pubmed.ncbi.nlm.nih.gov/9596583/)
97. Church VL, Francis-West P. Wnt signalling during limb development. *International Journal of Developmental Biology*. 2002; 46(7):927–936. PMID: [12455630](https://pubmed.ncbi.nlm.nih.gov/12455630/)
98. Farrell ER, Münsterberg AE. *csal1* is controlled by a combination of FGF and Wnt signals in developing limb buds. *Developmental biology*. 2000; 225(2):447–458. doi: [10.1006/dbio.2000.9852](https://doi.org/10.1006/dbio.2000.9852) PMID: [10985862](https://pubmed.ncbi.nlm.nih.gov/10985862/)
99. ten Berge D, Brugmann SA, Helms JA, Nusse R. Wnt and FGF signals interact to coordinate growth with cell fate specification during limb development. *Development*. 2008; 135(19):3247–3257. doi: [10.1242/dev.023176](https://doi.org/10.1242/dev.023176) PMID: [18776145](https://pubmed.ncbi.nlm.nih.gov/18776145/)
100. Saxén L, Sariola H. Early organogenesis of the kidney. *Pediatric nephrology*. 1987; 1(3):385–392. doi: [10.1007/BF00849241](https://doi.org/10.1007/BF00849241) PMID: [3153305](https://pubmed.ncbi.nlm.nih.gov/3153305/)
101. Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. *Developmental cell*. 2005; 9(2):283–292. doi: [10.1016/j.devcel.2005.05.016](https://doi.org/10.1016/j.devcel.2005.05.016) PMID: [16054034](https://pubmed.ncbi.nlm.nih.gov/16054034/)
102. Park JS, Valerius MT, McMahon AP. Wnt/ β -catenin signaling regulates nephron induction during mouse kidney development. *Development*. 2007; 134(13):2533–2539. doi: [10.1242/dev.006155](https://doi.org/10.1242/dev.006155) PMID: [17537789](https://pubmed.ncbi.nlm.nih.gov/17537789/)
103. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. *Nature*. 1994; 372(6507):679–683. doi: [10.1038/372679a0](https://doi.org/10.1038/372679a0) PMID: [7990960](https://pubmed.ncbi.nlm.nih.gov/7990960/)
104. Karner CM, Chirumamilla R, Aoki S, Igarashi P, Wallingford JB, Carroll TJ. Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. *Nature genetics*. 2009; 41(7):793–799. doi: [10.1038/ng.400](https://doi.org/10.1038/ng.400) PMID: [19543268](https://pubmed.ncbi.nlm.nih.gov/19543268/)
105. Burn S, Webb A, Berry R, Davies J, Ferrer-Vaquer A, Hadjantonakis A, et al. Calcium/NFAT signaling promotes early nephrogenesis. *Developmental biology*. 2011; 352(2):288–298. doi: [10.1016/j.ydbio.2011.01.033](https://doi.org/10.1016/j.ydbio.2011.01.033) PMID: [21295565](https://pubmed.ncbi.nlm.nih.gov/21295565/)

106. Tanigawa S, Wang H, Yang Y, Sharma N, Tarasova N, Ajima R, et al. Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. *Developmental biology*. 2011; 352(1):58–69. doi: [10.1016/j.ydbio.2011.01.012](https://doi.org/10.1016/j.ydbio.2011.01.012) PMID: [21256838](https://pubmed.ncbi.nlm.nih.gov/21256838/)
107. Mccoy KE, Zhou X, Vize PD. Non-canonical wnt signals antagonize and canonical wnt signals promote cell proliferation in early kidney development. *Developmental Dynamics*. 2011; 240(6):1558–1566. doi: [10.1002/dvdy.22626](https://doi.org/10.1002/dvdy.22626) PMID: [21465621](https://pubmed.ncbi.nlm.nih.gov/21465621/)
108. Simons M, Mlodzik M. Planar cell polarity signaling: from fly development to human disease. *Annual review of genetics*. 2008; 42:517. doi: [10.1146/annurev.genet.42.110807.091432](https://doi.org/10.1146/annurev.genet.42.110807.091432) PMID: [18710302](https://pubmed.ncbi.nlm.nih.gov/18710302/)
109. Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Krönig C, et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. *Nature genetics*. 2005; 37(5):537–543. doi: [10.1038/ng1552](https://doi.org/10.1038/ng1552) PMID: [15852005](https://pubmed.ncbi.nlm.nih.gov/15852005/)
110. Karner CM, Das A, Ma Z, Self M, Chen C, Lum L, et al. Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. *Development*. 2011; 138(7):1247–1257. doi: [10.1242/dev.057646](https://doi.org/10.1242/dev.057646) PMID: [21350016](https://pubmed.ncbi.nlm.nih.gov/21350016/)
111. Iglesias DM, Hueber PA, Chu L, Campbell R, Patenaude AM, Dziarmaga AJ, et al. Canonical WNT signaling during kidney development. *American Journal of Physiology-Renal Physiology*. 2007; 293(2):F494–F500. doi: [10.1152/ajprenal.00416.2006](https://doi.org/10.1152/ajprenal.00416.2006) PMID: [17494089](https://pubmed.ncbi.nlm.nih.gov/17494089/)
112. Lyons JP, Miller RK, Zhou X, Weidinger G, Deroo T, Denayer T, et al. Requirement of Wnt/ β -catenin signaling in pronephric kidney development. *Mechanisms of development*. 2009; 126(3):142–159. doi: [10.1016/j.mod.2008.11.007](https://doi.org/10.1016/j.mod.2008.11.007) PMID: [19100832](https://pubmed.ncbi.nlm.nih.gov/19100832/)
113. Schneider J, Arraf AA, Grinstein M, Yelin R, Schultheiss TM. Wnt signaling orients the proximal-distal axis of chick kidney nephrons. *Development*. 2015; 142(15):2686–2695. doi: [10.1242/dev.123968](https://doi.org/10.1242/dev.123968) PMID: [26116665](https://pubmed.ncbi.nlm.nih.gov/26116665/)
114. Lancaster MA, Gleeson JG. Cystic kidney disease: the role of Wnt signaling. *Trends in molecular medicine*. 2010; 16(8):349–360. doi: [10.1016/j.molmed.2010.05.004](https://doi.org/10.1016/j.molmed.2010.05.004) PMID: [20576469](https://pubmed.ncbi.nlm.nih.gov/20576469/)
115. Luyten A, Su X, Gondela S, Chen Y, Rompani S, Takakura A, et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. *Journal of the American Society of Nephrology*. 2010; 21(9):1521–1532. doi: [10.1681/ASN.2010010127](https://doi.org/10.1681/ASN.2010010127) PMID: [20705705](https://pubmed.ncbi.nlm.nih.gov/20705705/)
116. Chow RL, Lang RA. Early eye development in vertebrates. *Annual review of cell and developmental biology*. 2001; 17(1):255–296. doi: [10.1146/annurev.cellbio.17.1.255](https://doi.org/10.1146/annurev.cellbio.17.1.255) PMID: [11687490](https://pubmed.ncbi.nlm.nih.gov/11687490/)
117. Heisenberg CP, Houart C, Takeuchi M, Rauch GJ, Young N, Coutinho P, et al. A mutation in the Gsk3-binding domain of zebrafish Masterblind/Axin1 leads to a fate transformation of telencephalon and eyes to diencephalon. *Genes & Development*. 2001; 15(11):1427–1434. doi: [10.1101/gad.194301](https://doi.org/10.1101/gad.194301) PMID: [11390362](https://pubmed.ncbi.nlm.nih.gov/11390362/)
118. Kim CH, Oda T, Itoh M, Jiang D, Artinger KB, Chandrasekharappa SC, et al. Repressor activity of Headless/Tcf3 is essential for vertebrate head formation. *Nature*. 2000; 407(6806):913–916. doi: [10.1038/35038097](https://doi.org/10.1038/35038097) PMID: [11057671](https://pubmed.ncbi.nlm.nih.gov/11057671/)
119. Jasoni C, Hendrickson A, Roelink H. Analysis of chicken Wnt-13 expression demonstrates coincidence with cell division in the developing eye and is consistent with a role in induction. *Developmental dynamics*. 1999; 215(3):215–224. doi: [10.1002/\(SICI\)1097-0177\(199907\)215:3%3C215::AID-AJA4%3E3.3.CO;2-N](https://doi.org/10.1002/(SICI)1097-0177(199907)215:3%3C215::AID-AJA4%3E3.3.CO;2-N) PMID: [10398532](https://pubmed.ncbi.nlm.nih.gov/10398532/)
120. Cho SH, Cepko CL. Wnt2b/ β -catenin-mediated canonical Wnt signaling determines the peripheral fates of the chick eye. *Development*. 2006; 133(16):3167–3177. doi: [10.1242/dev.02474](https://doi.org/10.1242/dev.02474) PMID: [16854977](https://pubmed.ncbi.nlm.nih.gov/16854977/)
121. Kubo F, Takeichi M, Nakagawa S. Wnt2b controls retinal cell differentiation at the ciliary marginal zone. *Development*. 2003; 130(3):587–598. doi: [10.1242/dev.00244](https://doi.org/10.1242/dev.00244) PMID: [12490564](https://pubmed.ncbi.nlm.nih.gov/12490564/)
122. Jin EJ, Burrus LW, Erickson CA. The expression patterns of Wnts and their antagonists during avian eye development. *Mechanisms of development*. 2002; 116(1):173–176. doi: [10.1016/S0925-4773\(02\)00128-4](https://doi.org/10.1016/S0925-4773(02)00128-4) PMID: [12128219](https://pubmed.ncbi.nlm.nih.gov/12128219/)
123. Kubo F, Takeichi M, Nakagawa S. Wnt2b inhibits differentiation of retinal progenitor cells in the absence of Notch activity by downregulating the expression of proneural genes. *Development*. 2005; 132(12):2759–2770. doi: [10.1242/dev.01856](https://doi.org/10.1242/dev.01856) PMID: [15901663](https://pubmed.ncbi.nlm.nih.gov/15901663/)
124. Jidigam VK, Gunhaga L. Development of cranial placodes: insights from studies in chick. *Development, growth & differentiation*. 2013; 55(1):79–95. doi: [10.1111/dgd.12027](https://doi.org/10.1111/dgd.12027) PMID: [23278869](https://pubmed.ncbi.nlm.nih.gov/23278869/)
125. Grocott T, Johnson S, Bailey AP, Streit A. Neural crest cells organize the eye via TGF- β and canonical Wnt signalling. *Nature communications*. 2011; 2:265. doi: [10.1038/ncomms1269](https://doi.org/10.1038/ncomms1269) PMID: [21468017](https://pubmed.ncbi.nlm.nih.gov/21468017/)

126. Fokina VM, Frolova EI. Expression patterns of Wnt genes during development of an anterior part of the chicken eye. *Developmental dynamics*. 2006; 235(2):496–505. doi: [10.1002/dvdy.20621](https://doi.org/10.1002/dvdy.20621) PMID: [16258938](https://pubmed.ncbi.nlm.nih.gov/16258938/)
127. Traboulsi EI. Ocular manifestations of familial adenomatous polyposis (Gardner syndrome). *Ophthalmology clinics of North America*. 2005; 18(1):163–6. doi: [10.1016/j.ohc.2004.08.003](https://doi.org/10.1016/j.ohc.2004.08.003) PMID: [15763201](https://pubmed.ncbi.nlm.nih.gov/15763201/)
128. Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. *The American Journal of Human Genetics*. 2004; 74(3):558–563. doi: [10.1086/382196](https://doi.org/10.1086/382196) PMID: [14872406](https://pubmed.ncbi.nlm.nih.gov/14872406/)